AbbVie
NYSE: ABBV · Health Care · Biotechnology · NORTH CHICAGO, IL
Biopharma company led by immunology drugs Skyrizi and Rinvoq (succeeding Humira), plus neuroscience (Botox, Vraylar), oncology and aesthetics.
Annual results
Click any number to open the SEC filing it came from.
| Line | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| Net income | $11.5B | $11.8B | $4.9B | $4.3B | $4.2B |
| EPS — diluted | $6.45 per share | $6.63 per share | $2.72 per share | $2.39 per share | $2.36 per share |
| Cash from operations | $22.8B | $24.9B | $22.8B | $18.8B | $19.0B |
| Free cash flow | $22.0B | $24.2B | $22.1B | $17.8B | $17.8B |
| Total assets | $146.5B | $138.8B | $134.7B | $135.2B | $134.0B |
Recent filings
Members see much more
The full ABBV file, with an AI analyst on it.
- Quarterly statements, segments and IR data
- Valuation, earnings and insider activity
- A research assistant that cites the filing sentence